FilingSEC EDGAR8-K
enGene Reports Q3 Results and Clinical Updates
· SEC accepted
Filing content
enGene Therapeutics announced its financial results for the third quarter ended July 31, 2026, and reaffirmed plans for a pre-BLA meeting with the FDA by year-end.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…